نتایج جستجو برای: alteplase

تعداد نتایج: 6831  

Journal: :The New England journal of medicine 2012
Mark Parsons Neil Spratt Andrew Bivard Bruce Campbell Kong Chung Ferdinand Miteff Bill O'Brien Christopher Bladin Patrick McElduff Chris Allen Grant Bateman Geoffrey Donnan Stephen Davis Christopher Levi

BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...

2014
Nicola Logallo Christopher E Kvistad Aliona Nacu Halvor Naess Ulrike Waje-Andreassen Jörg Asmuss Anne Hege Aamodt Christian Lund Martin W Kurz Ole Morten Rønning Rolf Salvesen Titto T Idicula Lars Thomassen

BACKGROUND Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke T...

Journal: :Circulation 1999
M Moser T Nordt K Peter J Ruef B Kohler M Schmittner R Smalling W Kübler C Bode

BACKGROUND Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardia...

2012
Josef Yayan

Alteplase (recombinant tissue plasminogen activator) has been used in the treatment of acute ischemic stroke for 10 years. The application of this drug is considered safe and effective. However, alteplase is also associated with side effects. The author is reporting on an unusual side effect of angioedema that is triggered by alteplase. Angioedema occurs through alteplase according to this stud...

2003
Fedor Bachmann

Plasma levels of plasminogen activator inhibitor type-1 (PAI1). p-thromboglobulin (pTG), and fibrinopeptide A (FPA) were followed over 24 hours in 30 patients treated with alteplase for acute myocardial infarction. Samples were taken at baseline (T Oh), after 90 minutes (under alteplase, no heparin, T 1.5h). after 120 minutes (under alteplase and heparin, T 2h), 30 minutes after thrombolytic th...

Journal: :Stroke 2007
Emilio J Alegre Esmeralda Ríos

Alteplase for Patients With Ictus: the Dilemma Persists To the Editor: Therapeutic usefulness of alteplase in patients with ischemic stroke is a complex topic. Perhaps some clinical trials with good methodology exist; they are very different in patients, treatment and results. From a wide point of view, as of the Wardlaw et al metaanalysis,1 alteplase administration could increase all-cause mor...

Journal: :World journal of emergency medicine 2015
Seyran Bozkurt Engin Deniz Arslan Ataman Köse Cüneyt Ayrık Arda Yılmaz Güllü Akbaydoğan Dündar

BACKGROUND In recent years, thrombolytic therapy has become the main treatment of ischemic stroke. But the increasing use of alteplase in ischemic stroke has made some complications more evident. Angioedema is a rare but potentially life-threatening complication of alteplase treatment. Only a few studies have examined the incidence of angioedema after treatment with alteplase for stroke. METH...

2014
Jonathan Emberson Kennedy R Lees Patrick Lyden Lisa Blackwell Gregory Albers Erich Bluhmki Thomas Brott Geoff Cohen Stephen Davis Geoffrey Donnan James Grotta George Howard Markku Kaste Masatoshi Koga Ruediger von Kummer Maarten Lansberg Richard I Lindley Gordon Murray Jean Marc Olivot Mark Parsons Barbara Tilley Danilo Toni Kazunori Toyoda Nils Wahlgren Joanna Wardlaw William Whiteley Gregory J del Zoppo Colin Baigent Peter Sandercock Werner Hacke

BACKGROUND Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase. METHODS We did a pre-specified meta-analysis of individual pat...

Journal: :Journal of vascular and interventional radiology : JVIR 2002
Charles P Semba Steven R Deitcher Xin Li Laura Resnansky Tri Tu Edward R McCluskey

PURPOSE Thrombosis of central venous access devices (CVADs) is a relatively frequent complication. Alteplase (tissue plasminogen activator) has been used to salvage dysfunctional devices. The purpose of this study was to analyze the safety and efficacy of alteplase after administration of a maximum of two 2-mg/2-mL doses to thrombosed CVADs. MATERIALS AND METHODS A combined analysis was perfo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید